Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

This article was originally published in PharmAsia News

Executive Summary

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
Advertisement

Related Content

As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China
As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China
As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In Rising China
As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In Rising China
Bayer Looks To Singapore To Develop Cancer Drugs For Asian Patients
Bayer Looks To Singapore To Develop Cancer Drugs For Asian Patients
Bayer Guns For Top-Three Pharmaceutical Seat In China
Banner Week For Bayer In Japan
Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
Advertisement
UsernamePublicRestriction

Register

SC069171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel